Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 4

1(20.0%)

5Total

N/A(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06693011Not ApplicableRecruiting

Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)

Role: lead

NCT04852783Phase 4Active Not Recruiting

US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair

Role: lead

NCT04187573Not ApplicableCompleted

Coil Assisted Flow Diversion Safety and Performance Study

Role: lead

NCT02784431Terminated

Pilot Study of the Contour Neurovascular SystemTM

Role: lead

NCT04579081Withdrawn

Post Market Clinical Follow-up (PMCF)Study of the Contour Neurovascular SystemTM

Role: lead

NCT03680742Not ApplicableCompleted

Contour Neurovascular System - European Pre-Market Unruptured Aneurysm

Role: lead

NCT02507531Not ApplicableTerminated

INCA: Intracranial Aneurysm Treatment With NeXsys

Role: lead

All 7 trials loaded